AlphAIAlphAI — Financial news for AI agents
insights.citeline.comOCT 152 min read$LH

Labcorp To Pay Up To $872M For BioReference Health Assets, Including 4Kscore Prostate Test

Labcorp will pay up to $872M for OPKO Health's BioReference Health assets, including the 4Kscore prostate cancer test. The deal was announced on Oct. 15, 2023.

Original reporting
insights.citeline.com
Published Oct 15, 2026, 10:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 11:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Labcorp To Pay Up To $872M For BioReference Health Assets, Including 4Kscore Prostate Test — source image
Source · insights.citeline.com
Decision brief

The 30-second read

$LHBearishHigh
01

Why it matters

The acquisition expands Labcorp's diagnostic portfolio and may improve its competitive positioning in oncology testing, while OPKO receives a substantial cash payout.

02

Market read

The announcement is a material M&A event with immediate pricing implications for both LH and OPK.

03

What to watch

Regulatory approval timeline for the Kscore test and potential synergies with Labcorp's existing platform.

Relevance 9/10Novelty 9/10Timing: immediate reaction today

Background

Labcorp (LH) is a leading provider of clinical laboratory services; OPKO (OPK) owns BioReference Health, which operates the FDA-cleared Kscore prostate cancer blood test.

Company-level read

Ticker impact

$LHBearishHigh confidence
Context

Labcorp announced a $872M acquisition of OPKO's BioReference Health assets, a new primary disclosure affecting its valuation.

Expected impact

likely downside as the market prices in acquisition costs and integration risk

Evidence & confidence

Large cash outlay and integration uncertainty typically weigh on acquirer stock on announcement.

$OPKBullishHigh confidence
Context

OPKO agreed to sell BioReference Health assets to Labcorp for up to $872M, a fresh primary disclosure that could boost its share price.

Expected impact

likely upside as investors price in the cash proceeds

Evidence & confidence

Cash proceeds from a sizable asset sale generally lift the seller's stock.

Market effects

Sector

Consolidation in the clinical laboratory services sector may spur further M&A activity.

Regional

U.S. healthcare services market sees modest reallocation of capital.

Global

Limited to U.S. biotech and diagnostics investors.

Counterpoint

What could challenge this read

The deal could be accretive for Labcorp if the prostate test adds high-margin revenue, offsetting short-term dilution.

Key entities

  • Company
    Labcorp

    Acquirer, U.S.-listed ticker LH

  • Company
    OPKO Health

    Seller, U.S.-listed ticker OPK

Read at source← All news

StoryLabcorp to acquire OPKO’s BioReference assets for up to $872 million

Also covered by

6 outlets

Related articles

OCT 15
$LHHighAI 9/10

Labcorp Slides As Costly OPKO Deal Jolts Investors

Labcorp (LH) shares fell after announcing an $872M deal to acquire BioReference Health assets from OPKO, with up to $150M tied to the 4Kscore prostate cancer test's revenue. Investors are concerned about integration risks and cash outlay, though long-term growth prospects remain. Medicare reimbursement cuts and debt levels are additional risks.

tipranks.com2 min
OCT 15
$LHHighAI 9/10

Labcorp to Acquire BioReference Assets From OPKO for $872M

Labcorp agreed to acquire OPKO Health's remaining BioReference Health assets for up to $872M, including clinical diagnostics and the 4Kscore prostate cancer test. OPKO shares rose 20% premarket. The deal follows prior acquisitions of BioReference units, allowing OPKO to focus on biopharmaceuticals. Labcorp expects the acquired businesses to generate $250M in annual revenue.

hoodline.com3 min
OCT 15
$LHHighAI 9/10

Labcorp outlays up to $872m to acquire BioReference’s laboratory assets

Labcorp is acquiring laboratory assets from BioReference Health, an OPKO Health subsidiary, for up to $872m. The deal includes BioReference's clinical and women's health testing services, urology, corrections, and the 4Kscore prostate cancer test. Labcorp will pay $722m upfront, with up to $150m in potential earnouts. The transaction aims to expand Labcorp's diagnostic services and streamline OPKO's operations.

finance.yahoo.com2 min
OCT 15
$LHHighAI 9/10

Labcorp to buy BioReference assets for up to $872M

Labcorp will acquire laboratory testing assets from BioReference Health, an Opko Health subsidiary, for $722M, with up to $150M more contingent on prostate cancer test revenue. The total price may vary based on closing revenues, according to the companies.

finance.yahoo.com1 min
OCT 15
$OPKHighAI 9/10

OPKO Health Stock Jumps 16% On BioReference Asset Sale To Labcorp

OPKO Health (OPK) rose 16.13% to $1.5910 after agreeing to sell BioReference Health assets to Labcorp for $722M, with up to $150M in earnouts. The deal includes clinical testing businesses and the 4Kscore Test. Trading volume surged to 30.99M shares. OPK shares have ranged from $0.98 to $1.75 over the past year.

rttnews.com3 min